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Abstract
Alzheimer's disease and type 2 diabetes mellitus tend to occur together. We sought to identify
protein(s) common to both conditions that could suggest a possible unifying pathogenic role. Using
human neuronal butyrylcholinesterase (AAH08396.1) as the reference protein we used BLAST
Tool for protein to protein comparison in humans. We found three groups of sequences among a
series of 12, with an E-value between 0–12, common to both Alzheimer's disease and diabetes:
butyrylcholinesterase precursor K allele (NP_000046.1), acetylcholinesterase isoform E4-E6
precursor (NP_000656.1), and apoptosis-related acetylcholinesterase (1B41|A).
Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both
Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance
and lipid metabolism.
Background
Alzheimer's disease and type 2 diabetes mellitus occur
with increasing frequency as age advances. Besides, the
development of one increases the risk of the other [1]. Epi-
demiological studies have shown an association of diabe-
tes mellitus and Alzheimer's disease. A population-based
historical cohort study estimated that the risk of Alzhe-
imer's disease increased with adult onset diabetes mellitus
[2] A longitudinal study of 1,262 elderly subjects without
dementia at baseline, adjusted relative risk of Alzheimer's
disease among persons with diabetes was 1.3 [95% CI:
0.8, 1.9], [3]. In a more recent community-based study
among 1301 dementia-free persons aged 75 and above,
diabetes mellitus was associated with subsequent devel-
opment of Alzheimer's disease [4]. Similarly patients with
Alzheimer's disease were more vulnerable to developing
impaired fasting glucose and type 2 diabetes mellitus [5].
A variety of mechanisms has been postulated in the risk of
Alzheimer's disease and type 2 diabetes mellitus: meta-
bolic abnormalities of insulin resistance (dyslipidemia,
hypertension), hyperglycemia per se or insulin, by dis-
turbing synaptic plasticity, learning and memory [6].
The enzyme butyrylcholinesterase (EC 3.1.1.1.8) does not
have a well-defined physiological function, although it
may modulate the phenotypic expression of dyslipidemia
and insulin resistance. It is affected by dietary factors,
obesity, and dyslipidemia [5,7,8]
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While acetylcholinesterase in the brain is chiefly localized
to neurons, butyrylcholinesterase is primarily associated
with glial cells and endothelial cells [9].
Butyrylcholinesterase was studied in relation to both type
2 diabetes mellitus and Alzheimer's disease in different
ethnic groups [10-13].
Despite originating from the endoderm, the pancreas is
highly innervated and shares molecular similarities with
brain at the level of transcriptome and proteome [14].
Localized and progressive amyloidosis is characteristic of
both type 2 diabetes and Alzheimer's disease. Neurofibril-
lary tangles, the manifestations of pancreatic islet neuro-
degeneration have not been as extensively studied in
diabetes mellitus as in Alzheimer's disease. Cytotoxic
effects of fibril in both conditions involve an interaction
of cell membranes with mis-folded insoluble peptides
[15]. The two may therefore be mediated by common reg-
ulatory elements.
Considering that butyrylcholinesterase was associated
with both type 2 diabetes mellitus and with Alzheimer's
disease, and that leads existed for the a role of butyrylcho-
linesterase in their pathogeneses, we chose it as the refer-
ence protein. In addition, genetic variants of the enzyme
exist, which may play a role in biological fitness of indi-
viduals [16]. Identification of such sequences would pro-
vide leads for further understanding etiological,
therapeutic or prognostic aspects [17-20].
Data was retrieved from National Centre for Biotechnol-
ogy Information (NCBI). We took the amino acid
sequence of human neuronal butyrylcholinesterase
(AAH08396.1) as the reference protein and copied it to
Word programme in FASTA format. We used BLAST tool
in NCBI, and performed protein to protein comparison in
humans from the available databases. Taking E-value
between 0–12, we obtained 12 sequences that were com-
mon to both Alzheimer's disease and diabetes mellitus
(Table 1). The E-value refers to the probability due to
chance, that there is another alignment with a similarity
greater than the given similarity score. In general, An E<e-
5 of an alignment means that that alignment is highly
unique, and not due to error, whereas an E ≥ e-6 means
that the alignment might be strong, but more research is
needed to verify. The lower the E value, the more signifi-
cant the score.
The following sequences were obtained (Table 1):
Essentially the sequences may be grouped into butyryl-
cholinesterase precursor K allele (NP_000046.1), acetyl-
cholinesterase isoform E4-E6 precursor (NP_000656.1),
and apoptosis-related acetylcholinesterase (1B41|A).
Dementia and diabetes increase with age. This is related to
the occurrence of atherosclerosis, advanced glycation end
product, oxidative stress and the deposit of amyloid. [1,5].
Neurofibrillary tangles are deposited in brain of Alzhe-
imer's disease, along with senile plaques, which also con-
tain extraceullular deposits of human amyloid beta
peptide. Amyloid deposits, consisting of elongated
unbranched fibrils that bind to Congo Red dye, consist of
among others, acetylcholinesterase and apolipoprotein E
[21]. Amyloid fibrils are also seen in pancreatic beta cells
in type 2 diabetes mellitus [22]. Association of butyryl-
cholinesterase with Alzheimer's disease showed conflict-
ing results: some showed positive associations of BChE
polymorphism acting in synergy with APOE 4 [10], others
no significant differences while yet others protection
among women. The rationale for looking at the associa-
tion is that BChE gene codes for butyrylcholinesterase,
which is found in amyloid plaque [23]. BChE acts in con-
cert with apolipoprotein E which are both astrocyte pro-
Table 1: Sequences common to Alzheimer's Disease and Diabetes mellitus
SeqA Name Len(aa) SeqB Name Len(aa) E-Score*
1 AAH08396.1 64 CHLE_HUMAN 602 4e-34
2 AAH08396.1 64 NP_000046.1 602 4e-34
3 AAH08396.1 64 NP_000656.1 614 1e-16
4 AAH08396.1 64 BAD97163.1 614 1e-16
5 AAH08396.1 64 1F8U|A 583 2e-16
6 AAH08396.1 64 AAO32948.1 526 3e-16
7 AAH08396.1 64 AAH94752.1 640 2e-15
8 AAH08396.1 64 AAK21003.1 94 6e-13
9 AAH08396.1 64 1P0Q|A 529 3e-05
10 AAH08396.1 64 1VZJ|H 40 0.001
11 AAH08396.1 64 AAU43801.1 617 0.14
12 AAH08396.1 64 1B41|A 539 0.20
* The E-value refers to the probability due to chance, that there is another alignment with a similarity greater than the given similarity scoreLipids in Health and Disease 2006, 5:28 http://www.lipidworld.com/content/5/1/28
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teins that interact with lipoproteins after being released
into the circulation by the liver.
The variable association of BchE and variants with Alzhe-
imer's disease [10,23-25] was attributed to ethnic differ-
ences in frequency of BChE variants, perhaps due to
hidden population admixture, or of variant BChE being in
'linkage disequilibrium with an as yet unidentified AD
susceptibility gene in some populations [12].
Studies have linked BchE with the pathogenesis of Alzhe-
imer's disease and diabetes mellitus. BchE may modify the
risk of Alzheimer's disease either alone, or in synergy with
apoE-epsilon 4 [13]. Its active involvement is also sug-
gested by plaque area of demented brains having higher
BchE, and by its localization in neurofibrillary tangles, a
pathological hallmark of Alzheimer's disease. A recent
study showed that BchE attenuates amyloid formation by
an interaction of C terminus with soluble species of beta
amyloid in a polar environment [26]. It may prolong
nucleation phase and reduce propogation phase of fibril
formation and suppress amyloid fibril formation
enhanced by purified AchE-S [26]. Similarly selective inhi-
bition of BchE in aged rats improved cognitive navigation
[9]. In cultured neuroblastoma cells, selective BchE inhi-
bition reduced beta amyloid precursor protein and beta
amyloid peptide levels. It is supportive in the hydrolysis of
acetylcholinesterase and can partly compensate for the
action of AchE. While AchE levels are reduced early in
Alzheimer's disease, BchE levels rise with disease; selective
BchE inhibition may be useful to ameliorate cholinergic
defect. Therefore BchE may have a role in coregulating
local concentrations of acetylcholinesterase in Alzhe-
imer's disease.
BchE may be involved in the pathogenesis of type 2 diabe-
tes either by way of amyloid fibrils or by modifying other
risk factors of insulin resistance. Amyloid fibrils in pancre-
atic islets produce excessive superoxide radicals, lipid per-
oxidation and nitric oxide inactivation, contributing to
apoptosis of beta cells [15]. K variant of BchE have pro-
pensity for beta sheet formation, which may be related to
amyloidogenesis. In addition, a locus on chromosome
3q27, which is close to the chromosomal locus of BchE
was linked to type 2 diabetes mellitus in a French popula-
tion [27].
In addition, increased BchE may predispose aging cells to
oxidative stress [16].
Conventional association studies with evaluation of lim-
ited phenotypes are laborious, and do not always give
unambiguous answers proportionate to the effort
incurred [15]. With the availability of nucleotide and
amino acid sequences, we performed a bioinformatics
approach to study butyrylcholinesterase-related proteins
in Alzheimer's disease and in type 2 diabetes mellitus.
Comparative genomic study across species provides a
more broad-based picture of proteins in terms of evolu-
tion; earlier we showed that butyrylcholinesterase (EC
3.1.1.1.8) and its variants were spread in mammals con-
sistent with their evolutionary space, and that homolo-
gous sequences were expressed in other life forms,
including plants and bacteria [11,28].
Butyrylcholinesterase (NP_000046.1, Table 1) whose gene
is localized to a single autosomal location at 3q26 has
extensive homology to other cholinesterases of various
species. More than 30 genetic variants of BchE have been
reported, and the number is increasing. The occurrence of
such preadaptative pharmacogenetic variants was attrib-
uted to either balanced polymorphisms or to neutral
mutations [29].
A recent in vitro study showed that BchE attenuates amy-
loid fibril formation [9]. The association of BchE K variant
in both Alzheimer's disease [10] and type 2 diabetes mel-
litus suggests a possible pathogenic role in both diseases.
Acetylcholinesterase  (NP_000656.1, Table 1) regulates
cholinergic nerve and neuromuscular transmission; the
gene encoding this protein is mapped to chromosome 7.
Acetylcholinesterase belongs to the family of hydrolases
along with butyrylcholinesterase, with which it has 53%
sequence homology [17].
Acetylcholinesterase-like proteins were shown to mediate
cytoarchitectural changes that support neurotogenesis
[30]. It also has a role in human neocortical neuroplastic
processes [31].
There is substantial structural and functional evidence
linking acetylcholinesterase to Alzheimer's disease: a
region near C-terminus is weakly homologous to the N-
terminus of amyloid-beta peptide [32]. In a comparative
study on neurotoxicity comparison, human amyloid-beta
peptide fibrils complexed with acetylcholinesterase
showed greater toxicity than amyloid beta peptide fibrils
along [21]. Acetylcholinesterase may potentiate both
amyloid deposition and the toxicity of such deposits.
A recent study showed that hydrogen peroxide may be a
regulator of AchE [33]. The reaction is similar to that
which occurs in vitiligous skin, resulting in severe oxida-
tive stress [34]. Similarly, increased membrane AchE activ-
ity was attributed to high homocysteine levels, which are
correlated with neurological problems [34]. Oxidative
stress could result from hyperhomocystinemia, leading to
neuronal apoptosis [35] and to insulin resistance [36].Lipids in Health and Disease 2006, 5:28 http://www.lipidworld.com/content/5/1/28
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Similar suppression of butyrylcholinesterase has been
shown to occur with homocysteine, probably acting via
free radicals [35]
Apoptosis-related acetylcholinesterase (AAO32948.1) is an
alternatively-spliced variant expressed in blood cells, asso-
ciated with apoptosis. It could be a potential marker and
a regulator of apoptosis, being expressed in apoptotic
cells. Similarly it could be modulate pro-inflammatory
cytokines in macrophages in the periphery, and be differ-
entially expressed by stress in the periphery and in the
central nervous system [37].
Insulin signaling abnormalities could be the underlying
mechanism affecting the outcome of Alzheimer's disease;
insulin resistance and disordered degradation of amyloid
seem to link diabetes mellitus with Alzheimer's disease
[38]. Insulin dysregulation could act in a variety of ways
including decreased cortical glucose utilization, oxidative
stress formation of advanced glycated proteins, increased
neurofibrillary formation and increased b-amyloid aggre-
gation through inhibition of insulin-degrading enzyme
[39]. Insulin resistance could therefore be a link between
Alzheimer's disease and type 2 diabetes mellitus [40].
Butyrylcholinesterase may be indirectly involved in the
pathogenesis of insulin resistance [41]. It has been
hypothesized that peripheral insulin resistance can affect
CNS insulin levels, cognition and amyloid beta levels
[40]. Peripheral insulin resistance downregulate insulin
uptake at the blood brain barrier and lead to CNS
insulinopenia. Since insulin promotes intracellular amy-
loid beta release and alters expression of insulin degrad-
ing enzyme, low brain insulin levels can lead to amyloid
beta accumulation in neurons. Peripheral insulin resist-
ance may also inhibit clearance of amyloid beta from the
brain to the periphery, either by blocking its transport
from the brain or by interference with clearance in periph-
eral sites. Thus there could be a combination of accumu-
lation of amyloid beta, with decreased clearance, both due
to insulin resistance [40].
Antidiabetic drugs could be potentially useful in treating
Alzheimer's disease: PPAR gamma agonists, by improving
insulin sensitivity, decreasing inflammation and improv-
ing cerebral energy metabolism; intranasal insulin, by
restoring brain insulin levels in Alzheimer's disease [40].
Another intriguing aspect is the occurrence of variant
butyrylcholinesterases with low enzyme activity in certain
ethnic populations [16]. It would be instructive to study
the prevalence and course of both insulin resistance and
Alzheimer's disease in these individuals who may be con-
sidered to be on butyrylcholinesterase inhibitors. Such
studies are particularly instructive, considering that other
forms of treatment such as beta-secretase inhibitors may
be associated with potential negative consequences [42].
Individuals with BchE deficiency have been known to sur-
vive without any apparent adverse physiological conse-
quences.
In summary, esterase group of enzymes may be an under-
lying thread in the coexistence of Alzheimer's disease and
diabetes mellitus.
At present however, one cannot impute a direct cause-
effect relationship among the variables discussed here
(Alzheimer's disease, type 2 diabetes mellitus, insulin
resistance, butyrylcholinesterase), although there are epi-
demiological, biochemical, pathological and now compu-
tational biological leads pointing to an association. In line
with emerging paradigms of "in vivo to in silico biology
and back" [43], our results offer direction in the iterative
processes that drive biology forward in comprehending
biological phenomena.
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